SCP
CBAY

Sender Company & Partners’s Cymabay Therapeutics CBAY Stock Holding History

Sender Company & Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-61,080
Closed -$206K – 114
2021
Q4 		$206K Buy
+61,080
New +$232K 0.11% 89

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Sender Company & Partners's CBAY Position: Q1 2022 in Review

Sender Company & Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2022, closing a stake of 61,080 shares — an estimated $206K sold.

Sender Company & Partners first reported a position in CBAY in Q4 2021 and held it in 1 quarter. The position peaked at $206K in Q4 2021. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Sender Company & Partners reported no remaining Cymabay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 61,080 Cymabay Therapeutics shares in Q1 2022, an estimated $206K.
  • Sender Company & Partners first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Cymabay Therapeutics position peaked at $206K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.